Research and Clinical Trials
The Henry Ford IBD Center is on the forefront of IBD data collection, research and clinical trials of new treatments. Through these studies, our patients to have access to the latest advancements in IBD care.
Henry Ford IBD Center clinical studies
Clinical Trial of Etrolizumab for Ulcerative Colitis and Crohn's Disease: This drug works in a novel way to block intestinal inflammation. Eligible patients must have moderate to severe disease, be 18-80 years old, and have not responded well to previous treatment. This study requires clinical visits every 2-4 weeks and participants will be compensated for each visit. To determine eligibility and for more information, call Liz Schwartz, R.N., at (248) 344-2356.
Other ongoing drug therapy trials include studies evaluating the following:
- Effectiveness and safety of Humira (Adalimumab) in patients with moderately to severely active ulcerative colitis
- Safety and outcomes in pregnancy for patients with IBD
- Safety and outcomes in patients on Cimzia (certolizumab)